Anavex Life Sciences Corp (AVXL)

[TempePhil]

I confirmed US Rett trial was over enrolled from 21 by 50%. (Anavex IR)
So there are likely >30 patients.

This raises questions as to why this occurred for Anavex, and can we expect similar, or faster enrollment in our other two Rett trials.

1) Referencing Joanne Fagg's article "Newron’s failure in Rett syndrome leaves the late-stage pipeline to GW Pharma, Acadia and Anavex".
(https://www.evaluate.com/vantage/articles/news/trial-results/rett-failure-sets-thin-pipeline)
The idea is that there are fewer Rett trials going on now, so interested Rett patients have fewer possible trials to sign up for.

2) Another factor may be Anavex's good planning to cope with the Wuhan Virus, allowing at home visits, remote evaluations, etc. Prospective caregivers\patients would likely be interested in a caregivers\patients friendly plan.

3) Maybe with more people at home (Wuhan Virus), Rett caregivers had more time for evaluations.

Not only is the higher patient count better for signal refinement and statistics, but one could make a reasonable argument that our other Rett trials may see faster enrollment.